yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q36959425-170D5CFB-B582-46AF-85CE-B0F674E785D3
Q36959425-170D5CFB-B582-46AF-85CE-B0F674E785D3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36959425-170D5CFB-B582-46AF-85CE-B0F674E785D3
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study
P2860
Q36959425-170D5CFB-B582-46AF-85CE-B0F674E785D3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36959425-170D5CFB-B582-46AF-85CE-B0F674E785D3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
924adfe31db7844d8ee168e7ff99ed1b0899add4
P2860
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.